Muhit Özcan, MD, on DLBCL: Now Recruiting Previously Untreated Patients for a Study of Zilovertamab Vedotin Plus Chemotherapy
2023 ASCO Annual Meeting
Muhit Özcan, MD, of Turkey’s Ankara University School of Medicine, discusses waveLINE-007, a two-part study now recruiting in more than 20 locations, to determine the safety and recommended phase II dose of the antibody-drug conjugate zilovertamab vedotin in combination with R-CHP (rituximab, cyclophosphamide, doxorubicin, prednisone) in previously untreated patients with diffuse large B-cell lymphoma (DLBCL). Efficacy of this regimen will be investigated in the second half of the study (Abstract TPS7589).
Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Diffuse large B-cell lymphoma is typically treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone, a regimen known as R-CHOP, but novel therapies are needed. A recent phase III study showed that replacing vincristine in R-CHOP with the antibody-drug conjugate polatuzumab vedotin was a viable approach in diffuse large B-cell lymphoma.
ROR1 is an onco-fetal transmembrane protein that's expressed in a number of hematological malignancies, including diffuse large B-cell lymphomas. Zilovertamab vedotin is an antibody-drug conjugate comprising an anti-ROR1 antibody plus a cleavable linker, and the antimicrotubule cytotoxin monomethyl auristatin E, that has shown promising efficacy and manageable safety in patients with relapse or refractory hematological malignancies. The single-arm, open-label, phase II waveLINE-007 study has been designed to investigate zilovertamab vedotin in combination with R-CHP in patients with previously untreated diffuse like B cell lymphomas.
Part one is being conducted to determine the safety and tolerability and recommended phase II dose of zilovertamab vedotin plus R-CHOP. Part two will be conducted to investigate the efficacy of zilovertamab vedotin plus R-CHP at the recommended phase II dose. The primary objectives of waveLINE-007 are to evaluate complete response rate based on Lugano criteria and to evaluate the safety and tolerability of zilovertamab vedotin plus R-CHP. Secondary objectives include evaluating objective response rate and the duration of response per Lugano criteria. Progression-free survival, overall survival, and the pharmacokinetics of zilovertamab vedotin plus R-CHP are exploratory.
In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients will receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a minimum of 2.5 milligram per kilogram, with the target dose limiting toxicity rate of 30%.
In part one, which is the dose escalation and confirmation part of the study, approximately 45 patients with receive treatment with zilovertamab vedotin plus R-CHP. The starting dose of zilovertamab vedotin is 1.75 milligram per kilogram plus R-CHP administered intravenously every 3 weeks for six cycles. Dose escalation will be based on the modified toxicity probability interval design up to a maximum of 2.5 milligram per kilogram, with a target dose limiting toxicity rate of 30%. In the event of dose-limiting toxicities at the starting dose, the dose can also be deescalated to 1.5 milligram per kilogram.
In part two, approximately 30 patients with received zilovertamab vedotin at the recommended phase II dose plus R-CHP intravenously every 3 weeks for six cycles or up to eight cycles for patients with high-risk disease. Eligible patients must be 18 years or older, have histologically confirmed diffuse large B cell lymphoma per WHO criteria, have PET-positive disease, have an ECOG performance status 0 or 1, and have an adequate organ function. Patients must not have received prior treatments for diffuse large B cell lymphoma patients with a history of transformation of indolent disease at diagnosis of primary mediastinal B-cell lymphoma, ongoing peripheral neuropathy of grade 2 or higher, or active central nervous system lymphoma will be excluded. Recruitment for waveLINE-007 is currently ongoing in Canada, Israel, Italy, Poland, Korea, Spain, and Turkey. Results from the waveLINE-007 study will provide insight into the efficacy and safety of zilovertamab vedotin plus R-CHP in patients with previously untreated diffuse large B-cell lymphomas.
Jonathan W. Riess, MD, of the University of California, Davis Comprehensive Cancer Center, explores the findings of three important clinical trials in lung cancer treatment: whether to incorporate immune checkpoint inhibitors into the treatment of EGFR-mutated lung cancer, the importance of central nervous system activity in EGFR-mutant lung cancer, and new therapies for disease with EGFR exon 20 insertion.
Georgina V. Long, MD, PhD, of Melanoma Institute Australia and The University of Sydney, discusses new data showing that patients with resected stage IIB/C melanoma who were treated with adjuvant nivolumab had prolonged recurrence-free survival compared with placebo across all biomarker subgroups. The baseline biomarkers most predictive of prolonged recurrence-free survival with nivolumab were high interferon gamma score, high tumor mutational burden, CD8 T-cell infiltration, and low C-reactive protein (Abstract 9504).
Carmen E. Guerra, MD, MSCE, of the University of Pennsylvania Abramson Cancer Center, discusses three key abstracts presented at ASCO: strategies to increase accrual of underrepresented populations in Alliance NCTN trials, how patient-clinician education can strengthen partnerships and improve diversity in breast and lung cancer trials, and mediators of racial and ethnic inequities in clinical trial participation among U.S. patients with cancer from 2011 to 2022 (Abstracts 6509, 6510, 6511).
Narjust Florez, MD, of Dana-Farber Cancer Institute, and Filippo Gustavo Dall’Olio, MD, of Institut Gustave Roussy, discuss circulating tumor DNA tumor fraction, and its link to survival in patients with advanced non–small cell lung cancer (NSCLC) treated with maintenance durvalumab in the UNICANCER SAFIR02-Lung/IFCT1301 trial. Tumor fraction was positive in 16% of patients randomly assigned to receive durvalumab in the study. This population seems to have a limited benefit from maintenance durvalumab after induction chemotherapy (Abstract 2516).
Omid Hamid, MD, of The Angeles Clinic & Research Institute, discusses study findings on fianlimab plus cemiplimab-rwlc, which showed clinical activity in patients with advanced melanoma, comparing favorably with other approved combinations of immune checkpoint inhibitors in the same clinical setting. This is the first indication that dual LAG-3 blockade may produce a high level of activity with significant overall response rate after adjuvant anti–PD-1 treatment. A phase III trial of this regimen in treatment-naive patients with advanced melanoma is ongoing (Abstract 9501).